Response to hepatitis B virus vaccination in individuals with chronic hepatitis C virus infection.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
07
03
2020
accepted:
25
07
2020
entrez:
27
8
2020
pubmed:
28
8
2020
medline:
21
10
2020
Statut:
epublish
Résumé
Previous reports show conflicting results regarding hepatitis B virus (HBV) vaccine efficacy in Hepatitis C virus (HCV)-infected individuals. To evaluate HBV-vaccine response and identify possible factors that may contribute to lower vaccine efficacy in patients infected with HCV. We retrospectively evaluated all patients with chronic HCV infection at Hennepin County Medical Center, in Minneapolis, Minnesota, between 2002 and 2018. We addressed laboratory, liver-related, virus-related as well as vaccine-related variables, and their association to HBV vaccine response. Differences were tested using either a Chi-squared test or a T test to compare means between the two populations. Multivariate regression was modeled as a logistic regression. 1506 patients were evaluated, of which 525 received appropriate HBV vaccination and were assessed for response. Among those, 79% were vaccine responders and 21% were non-responders. On multivariate analysis, cirrhosis was associated with lower response to the vaccine (OR 0.6, CI 0.44-0.94). We found no significant differences for vaccine response in relation to smoking (87% vs 86%), IV drug abuse (74% vs 72%), Diabetes Mellitus (26% vs 22%) being on hemodialysis (2% vs.5%), or virus related variables. HCV infection seems to impair HBV vaccine response, with cirrhosis being the only identifiable risk factor for hypo-responsiveness among studied clinical and virus-related variables.
Sections du résumé
BACKGROUND
Previous reports show conflicting results regarding hepatitis B virus (HBV) vaccine efficacy in Hepatitis C virus (HCV)-infected individuals.
AIMS
To evaluate HBV-vaccine response and identify possible factors that may contribute to lower vaccine efficacy in patients infected with HCV.
METHODS
We retrospectively evaluated all patients with chronic HCV infection at Hennepin County Medical Center, in Minneapolis, Minnesota, between 2002 and 2018. We addressed laboratory, liver-related, virus-related as well as vaccine-related variables, and their association to HBV vaccine response. Differences were tested using either a Chi-squared test or a T test to compare means between the two populations. Multivariate regression was modeled as a logistic regression.
RESULTS
1506 patients were evaluated, of which 525 received appropriate HBV vaccination and were assessed for response. Among those, 79% were vaccine responders and 21% were non-responders. On multivariate analysis, cirrhosis was associated with lower response to the vaccine (OR 0.6, CI 0.44-0.94). We found no significant differences for vaccine response in relation to smoking (87% vs 86%), IV drug abuse (74% vs 72%), Diabetes Mellitus (26% vs 22%) being on hemodialysis (2% vs.5%), or virus related variables.
CONCLUSION
HCV infection seems to impair HBV vaccine response, with cirrhosis being the only identifiable risk factor for hypo-responsiveness among studied clinical and virus-related variables.
Identifiants
pubmed: 32845914
doi: 10.1371/journal.pone.0237398
pii: PONE-D-20-06696
pmc: PMC7449383
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0237398Subventions
Organisme : NCI NIH HHS
ID : R21 CA215883
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Tissue Antigens. 1997 Jul;50(1):8-14
pubmed: 9243749
Vaccine. 2000 Oct 15;19(4-5):437-41
pubmed: 11027806
World J Gastroenterol. 2006 Jul 21;12(27):4420-4
pubmed: 16865790
J Exp Med. 1992 Feb 1;175(2):495-502
pubmed: 1531063
Clin Infect Dis. 2006 Mar 1;42(5):673-6
pubmed: 16447113
J Coll Physicians Surg Pak. 2014 Jun;24(6):392-5
pubmed: 24953911
Immunogenetics. 1995;41(6):366-74
pubmed: 7759133
Z Gastroenterol. 2003 Oct;41(10):983-90
pubmed: 14562195
Hepatology. 2013 Aug;58(2):538-45
pubmed: 23505059
Hepatol Res. 2017 Dec;47(13):1438-1444
pubmed: 28585404
Int J Prev Med. 2014 Feb;5(2):145-51
pubmed: 24627739
J Immunol. 1999 Jan 15;162(2):931-8
pubmed: 9916717
Nephron Clin Pract. 2006;103(3):c89-93
pubmed: 16534237
Vaccine. 2011 Apr 12;29(17):3169-76
pubmed: 21376795
Clin Res Hepatol Gastroenterol. 2017 Dec;41(6):656-663
pubmed: 28867077
Diabetes Care. 2012 Dec;35(12):2690-7
pubmed: 23173138
Hepatology. 2000 Feb;31(2):521-7
pubmed: 10655280
Vaccine. 2006 Jan 30;24(5):572-7
pubmed: 16171909
Hepatogastroenterology. 2005 Nov-Dec;52(66):1803-8
pubmed: 16334781
Hepatology. 2012 Mar;55(3):709-19
pubmed: 21932384
J Med Virol. 1999 Dec;59(4):463-8
pubmed: 10534727
Hepatology. 2017 Jul;66(1):27-36
pubmed: 28240789
Sci Rep. 2016 Jun 21;6:27251
pubmed: 27324884
Hepatol Res. 2018 Feb;48(2):119-126
pubmed: 29197147
J Microbiol Immunol Infect. 2009 Apr;42(2):122-8
pubmed: 19597643
Eur J Gastroenterol Hepatol. 2002 May;14(5):485-9
pubmed: 11984145
J Hepatol. 2005 Jul;43(1):167-76
pubmed: 15925423
Hepatology. 2000 Jan;31(1):230-4
pubmed: 10613751
Lancet Infect Dis. 2017 Oct;17(10):1062-1068
pubmed: 28818546
Kidney Int. 2013 Sep;84(3):622-3
pubmed: 23989362
Ann Gastroenterol. 2015 Apr-Jun;28(2):221-228
pubmed: 25830779
Arq Gastroenterol. 2004 Jul-Sep;41(3):180-4
pubmed: 15678203
Med Sci Monit. 2002 May;8(5):CR379-83
pubmed: 12011781
Am J Kidney Dis. 2003 Dec;42(6):1184-92
pubmed: 14655190
Am J Med. 2005 Oct;118 Suppl 10A:21S-27S
pubmed: 16271537
N Engl J Med. 1999 Aug 19;341(8):556-62
pubmed: 10451460